Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

Waleed Hassen; Laura Motherway

doi:10.1007/978-3-030-52021-2_13

Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

Waleed Hassen
, Laura Motherway

Cleveland Clinic Abu Dhabi

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland Clinic Abu Dhabi

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Approximately 70% of the 81,400 newly diagnosed patients with bladder cancer present with non-muscle invasive urothelial carcinoma. Non-muscle invasive disease is associated with a high risk of recurrence and a lower but significant risk of disease progression with resultant increased morbidity and mortality. The goal of intravesical therapy is to reduce disease recurrence as well as progression. This chapter will discuss the various intravesical therapies that are available, including their mechanisms of actions and efficacy. Their clinical utility will be discussed as well as how to incorporate cystoscopy in the routine follow-up of these patients.

Original language	English
Title of host publication	Chemotherapy and Immunotherapy in Urologic Oncology
Subtitle of host publication	a Guide for the Advanced Practice Provider
Publisher	Springer International Publishing
Pages	159-168
Number of pages	10
ISBN (Electronic)	9783030520212
ISBN (Print)	9783030520205
DOIs	https://doi.org/10.1007/978-3-030-52021-2_13
State	Published - 1 Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

BCG
Cystoscopy
Immunotherapy
Intravesical chemotherapy

Access to Document

10.1007/978-3-030-52021-2_13

Cite this

@inbook{25940a81deec4e8cb12961de3a9a61e8,

title = "Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma",

abstract = "Approximately 70\% of the 81,400 newly diagnosed patients with bladder cancer present with non-muscle invasive urothelial carcinoma. Non-muscle invasive disease is associated with a high risk of recurrence and a lower but significant risk of disease progression with resultant increased morbidity and mortality. The goal of intravesical therapy is to reduce disease recurrence as well as progression. This chapter will discuss the various intravesical therapies that are available, including their mechanisms of actions and efficacy. Their clinical utility will be discussed as well as how to incorporate cystoscopy in the routine follow-up of these patients.",

keywords = "BCG, Cystoscopy, Immunotherapy, Intravesical chemotherapy",

author = "Waleed Hassen and Laura Motherway",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-3-030-52021-2\_13",

language = "English",

isbn = "9783030520205",

pages = "159--168",

booktitle = "Chemotherapy and Immunotherapy in Urologic Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

AU - Hassen, Waleed

AU - Motherway, Laura

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Approximately 70% of the 81,400 newly diagnosed patients with bladder cancer present with non-muscle invasive urothelial carcinoma. Non-muscle invasive disease is associated with a high risk of recurrence and a lower but significant risk of disease progression with resultant increased morbidity and mortality. The goal of intravesical therapy is to reduce disease recurrence as well as progression. This chapter will discuss the various intravesical therapies that are available, including their mechanisms of actions and efficacy. Their clinical utility will be discussed as well as how to incorporate cystoscopy in the routine follow-up of these patients.

AB - Approximately 70% of the 81,400 newly diagnosed patients with bladder cancer present with non-muscle invasive urothelial carcinoma. Non-muscle invasive disease is associated with a high risk of recurrence and a lower but significant risk of disease progression with resultant increased morbidity and mortality. The goal of intravesical therapy is to reduce disease recurrence as well as progression. This chapter will discuss the various intravesical therapies that are available, including their mechanisms of actions and efficacy. Their clinical utility will be discussed as well as how to incorporate cystoscopy in the routine follow-up of these patients.

KW - BCG

KW - Cystoscopy

KW - Immunotherapy

KW - Intravesical chemotherapy

UR - https://www.scopus.com/pages/publications/105018265817

U2 - 10.1007/978-3-030-52021-2_13

DO - 10.1007/978-3-030-52021-2_13

M3 - Chapter

AN - SCOPUS:105018265817

SN - 9783030520205

SP - 159

EP - 168

BT - Chemotherapy and Immunotherapy in Urologic Oncology

PB - Springer International Publishing

ER -

Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this